+Search query
-Structure paper
Title | Discovery of Nanosota-EB1 and -EB2 as Novel Nanobody Inhibitors Against Ebola Virus Infection. |
---|---|
Journal, issue, pages | PLoS Pathog, Vol. 20, Issue 12, Page e1012817, Year 2024 |
Publish date | Dec 23, 2024 |
![]() | Fan Bu / Gang Ye / Kimberly Morsheimer / Alise Mendoza / Hailey Turner-Hubbard / Morgan Herbst / Benjamin Spiller / Brian E Wadzinski / Brett Eaton / Manu Anantpadma / Ge Yang / Bin Liu / Robert Davey / Fang Li / ![]() |
PubMed Abstract | The Ebola filovirus (EBOV) poses a serious threat to global health and national security. Nanobodies, a type of single-domain antibody, have demonstrated promising therapeutic potential. We ...The Ebola filovirus (EBOV) poses a serious threat to global health and national security. Nanobodies, a type of single-domain antibody, have demonstrated promising therapeutic potential. We identified two anti-EBOV nanobodies, Nanosota-EB1 and Nanosota-EB2, which specifically target the EBOV glycoprotein (GP). Cryo-EM and biochemical data revealed that Nanosota-EB1 binds to the glycan cap of GP1, preventing its protease cleavage, while Nanosota-EB2 binds to critical membrane-fusion elements in GP2, stabilizing it in the pre-fusion state. Nanosota-EB2 is a potent neutralizer of EBOV infection in vitro and offers excellent protection in a mouse model of EBOV challenge, while Nanosota-EB1 provides moderate neutralization and protection. Nanosota-EB1 and Nanosota-EB2 are the first nanobodies shown to inhibit authentic EBOV. Combined with our newly developed structure-guided in vitro evolution approach, they lay the foundation for nanobody-based therapies against EBOV and other viruses within the ebolavirus genus. |
![]() | ![]() ![]() ![]() |
Methods | EM (single particle) |
Resolution | 3.1 - 3.36 Å |
Structure data | EMDB-44872, PDB-9bsu: EMDB-44873, PDB-9bsv: |
Chemicals | ![]() ChemComp-MAN: |
Source |
|
![]() | VIRAL PROTEIN / EBOV glycoprotein / nanobody |